1586 related articles for article (PubMed ID: 31942077)
1. B cells are associated with survival and immunotherapy response in sarcoma.
Petitprez F; de Reyniès A; Keung EZ; Chen TW; Sun CM; Calderaro J; Jeng YM; Hsiao LP; Lacroix L; Bougoüin A; Moreira M; Lacroix G; Natario I; Adam J; Lucchesi C; Laizet YH; Toulmonde M; Burgess MA; Bolejack V; Reinke D; Wani KM; Wang WL; Lazar AJ; Roland CL; Wargo JA; Italiano A; Sautès-Fridman C; Tawbi HA; Fridman WH
Nature; 2020 Jan; 577(7791):556-560. PubMed ID: 31942077
[TBL] [Abstract][Full Text] [Related]
2. Tertiary lymphoid structures improve immunotherapy and survival in melanoma.
Cabrita R; Lauss M; Sanna A; Donia M; Skaarup Larsen M; Mitra S; Johansson I; Phung B; Harbst K; Vallon-Christersson J; van Schoiack A; Lövgren K; Warren S; Jirström K; Olsson H; Pietras K; Ingvar C; Isaksson K; Schadendorf D; Schmidt H; Bastholt L; Carneiro A; Wargo JA; Svane IM; Jönsson G
Nature; 2020 Jan; 577(7791):561-565. PubMed ID: 31942071
[TBL] [Abstract][Full Text] [Related]
3. Activity of PD1 inhibitor therapy in advanced sarcoma: a single-center retrospective analysis.
Quiroga D; Liebner DA; Philippon JS; Hoffman S; Tan Y; Chen JL; Lenobel S; Wakely PE; Pollock R; Tinoco G
BMC Cancer; 2020 Jun; 20(1):527. PubMed ID: 32503455
[TBL] [Abstract][Full Text] [Related]
4. B cells and tertiary lymphoid structures promote immunotherapy response.
Helmink BA; Reddy SM; Gao J; Zhang S; Basar R; Thakur R; Yizhak K; Sade-Feldman M; Blando J; Han G; Gopalakrishnan V; Xi Y; Zhao H; Amaria RN; Tawbi HA; Cogdill AP; Liu W; LeBleu VS; Kugeratski FG; Patel S; Davies MA; Hwu P; Lee JE; Gershenwald JE; Lucci A; Arora R; Woodman S; Keung EZ; Gaudreau PO; Reuben A; Spencer CN; Burton EM; Haydu LE; Lazar AJ; Zapassodi R; Hudgens CW; Ledesma DA; Ong S; Bailey M; Warren S; Rao D; Krijgsman O; Rozeman EA; Peeper D; Blank CU; Schumacher TN; Butterfield LH; Zelazowska MA; McBride KM; Kalluri R; Allison J; Petitprez F; Fridman WH; Sautès-Fridman C; Hacohen N; Rezvani K; Sharma P; Tetzlaff MT; Wang L; Wargo JA
Nature; 2020 Jan; 577(7791):549-555. PubMed ID: 31942075
[TBL] [Abstract][Full Text] [Related]
5. Tertiary lymphoid structure signatures are associated with survival and immunotherapy response in muscle-invasive bladder cancer.
Zhou L; Xu B; Liu Y; Wang Z
Oncoimmunology; 2021 May; 10(1):1915574. PubMed ID: 34104539
[TBL] [Abstract][Full Text] [Related]
6. [Intratumoral B cells and tertiary lymphoid structures are biomarkers of survival and immunotherapy responses].
Fridman WH; Petitprez F; Sautes-Fridman C
Bull Cancer; 2020 Apr; 107(4):403-404. PubMed ID: 32284150
[No Abstract] [Full Text] [Related]
7. Tertiary Lymphoid Structures as a Predictive Biomarker of Response to Cancer Immunotherapies.
Trüb M; Zippelius A
Front Immunol; 2021; 12():674565. PubMed ID: 34054861
[TBL] [Abstract][Full Text] [Related]
8. The Immunosuppressive Niche of Soft-Tissue Sarcomas is Sustained by Tumor-Associated Macrophages and Characterized by Intratumoral Tertiary Lymphoid Structures.
Chen L; Oke T; Siegel N; Cojocaru G; Tam AJ; Blosser RL; Swailes J; Ligon JA; Lebid A; Morris C; Levin A; Rhee DS; Johnston FM; Greer JB; Meyer CF; Ladle BH; Thompson ED; Montgomery EA; Choi W; McConkey DJ; Anders RA; Pardoll DM; Llosa NJ
Clin Cancer Res; 2020 Aug; 26(15):4018-4030. PubMed ID: 32332015
[TBL] [Abstract][Full Text] [Related]
9. Immunotherapy for sarcomas.
Nakata E; Fujiwara T; Kunisada T; Ito T; Takihira S; Ozaki T
Jpn J Clin Oncol; 2021 Apr; 51(4):523-537. PubMed ID: 33611603
[TBL] [Abstract][Full Text] [Related]
10. The Tumor Immune Landscape and Architecture of Tertiary Lymphoid Structures in Urothelial Cancer.
van Dijk N; Gil-Jimenez A; Silina K; van Montfoort ML; Einerhand S; Jonkman L; Voskuilen CS; Peters D; Sanders J; Lubeck Y; Broeks A; Hooijberg E; Vis DJ; van den Broek M; Wessels LFA; van Rhijn BWG; van der Heijden MS
Front Immunol; 2021; 12():793964. PubMed ID: 34987518
[TBL] [Abstract][Full Text] [Related]
11. Immune checkpoint inhibitors in treatment of soft-tissue sarcoma: A systematic review and meta-analysis.
Saerens M; Brusselaers N; Rottey S; Decruyenaere A; Creytens D; Lapeire L
Eur J Cancer; 2021 Jul; 152():165-182. PubMed ID: 34107450
[TBL] [Abstract][Full Text] [Related]
12. A radiomics approach to assess tumour-infiltrating CD8 cells and response to anti-PD-1 or anti-PD-L1 immunotherapy: an imaging biomarker, retrospective multicohort study.
Sun R; Limkin EJ; Vakalopoulou M; Dercle L; Champiat S; Han SR; Verlingue L; Brandao D; Lancia A; Ammari S; Hollebecque A; Scoazec JY; Marabelle A; Massard C; Soria JC; Robert C; Paragios N; Deutsch E; Ferté C
Lancet Oncol; 2018 Sep; 19(9):1180-1191. PubMed ID: 30120041
[TBL] [Abstract][Full Text] [Related]
13. PD-1 blockade using pembrolizumab in adolescent and young adult patients with advanced bone and soft tissue sarcoma.
Scheinberg T; Lomax A; Tattersall M; Thomas D; McCowage G; Sullivan M; Karim R; Luk PP; Mahar A; Bonar F; Bhadri VA
Cancer Rep (Hoboken); 2021 Apr; 4(2):e1327. PubMed ID: 33314769
[TBL] [Abstract][Full Text] [Related]
14. Tertiary lymphoid structures show infiltration of effective tumor-resident T cells in gastric cancer.
Mori T; Tanaka H; Suzuki S; Deguchi S; Yamakoshi Y; Yoshii M; Miki Y; Tamura T; Toyokawa T; Lee S; Muguruma K; Wanibuchi H; Ohira M
Cancer Sci; 2021 May; 112(5):1746-1757. PubMed ID: 33735485
[TBL] [Abstract][Full Text] [Related]
15. Immune mechanisms orchestrate tertiary lymphoid structures in tumors via cancer-associated fibroblasts.
Rodriguez AB; Peske JD; Woods AN; Leick KM; Mauldin IS; Meneveau MO; Young SJ; Lindsay RS; Melssen MM; Cyranowski S; Parriott G; Conaway MR; Fu YX; Slingluff CL; Engelhard VH
Cell Rep; 2021 Jul; 36(3):109422. PubMed ID: 34289373
[TBL] [Abstract][Full Text] [Related]
16. Emerging Targeted and Immune-Based Therapies in Sarcoma.
Pollack SM; Ingham M; Spraker MB; Schwartz GK
J Clin Oncol; 2018 Jan; 36(2):125-135. PubMed ID: 29220291
[TBL] [Abstract][Full Text] [Related]
17. Tumor DNA methylation profiles correlate with response to anti-PD-1 immune checkpoint inhibitor monotherapy in sarcoma patients.
Starzer AM; Berghoff AS; Hamacher R; Tomasich E; Feldmann K; Hatziioannou T; Traint S; Lamm W; Noebauer-Huhmann IM; Furtner J; Müllauer L; Amann G; Bauer S; Schildhaus HU; Preusser M; Heller G; Brodowicz T
J Immunother Cancer; 2021 Mar; 9(3):. PubMed ID: 33762319
[TBL] [Abstract][Full Text] [Related]
18. T-cell infiltration and clonality correlate with programmed cell death protein 1 and programmed death-ligand 1 expression in patients with soft tissue sarcomas.
Pollack SM; He Q; Yearley JH; Emerson R; Vignali M; Zhang Y; Redman MW; Baker KK; Cooper S; Donahue B; Loggers ET; Cranmer LD; Spraker MB; Seo YD; Pillarisetty VG; Ricciotti RW; Hoch BL; McClanahan TK; Murphy E; Blumenschein WM; Townson SM; Benzeno S; Riddell SR; Jones RL
Cancer; 2017 Sep; 123(17):3291-3304. PubMed ID: 28463396
[TBL] [Abstract][Full Text] [Related]
19. Tertiary Lymphoid Structures: Autoimmunity Goes Local.
Pipi E; Nayar S; Gardner DH; Colafrancesco S; Smith C; Barone F
Front Immunol; 2018; 9():1952. PubMed ID: 30258435
[TBL] [Abstract][Full Text] [Related]
20. Sarcomas: Immune biomarker expression and checkpoint inhibitor trials.
Zhu MMT; Shenasa E; Nielsen TO
Cancer Treat Rev; 2020 Dec; 91():102115. PubMed ID: 33130422
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
